Compare BFC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | PHVS |
|---|---|---|
| Founded | 1894 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2018 | 2020 |
| Metric | BFC | PHVS |
|---|---|---|
| Price | $142.05 | $30.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $157.00 | $41.82 |
| AVG Volume (30 Days) | 73.3K | ★ 388.7K |
| Earning Date | 04-16-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 11.23 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.67 | N/A |
| Revenue Next Year | $2.01 | N/A |
| P/E Ratio | $79.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $109.11 | $15.51 |
| 52 Week High | $153.00 | $33.33 |
| Indicator | BFC | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 51.04 |
| Support Level | $140.47 | $24.73 |
| Resistance Level | $148.01 | $31.14 |
| Average True Range (ATR) | 3.42 | 1.54 |
| MACD | -0.49 | -0.16 |
| Stochastic Oscillator | 38.18 | 29.20 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.